PMC:7195088 / 65192-65750 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/7195088","sourcedb":"PMC","sourceid":"7195088","source_url":"https://www.ncbi.nlm.nih.gov/pmc/7195088","text":"In the absence of clinical studies, we suggest that also other immunosuppressive and/or immunomodulatory therapies (e.g. anakinra, Janus kinase family enzyme inhibitors) should be preferentially administered within RCT. This also applies to modifications of the immune response through high-dose intravenous immunoglobulins or plasma from convalescent patients, which, although promising in very small case series, both deserve dedicated RCT investigation to clearly understand their tolerability as well as the role they play in affecting COVID-19 outcomes.","tracks":[{"project":"LitCovid-PubTator","denotations":[{"id":"1906","span":{"begin":352,"end":360},"obj":"Species"},{"id":"1907","span":{"begin":540,"end":548},"obj":"Disease"}],"attributes":[{"id":"A1906","pred":"tao:has_database_id","subj":"1906","obj":"Tax:9606"},{"id":"A1907","pred":"tao:has_database_id","subj":"1907","obj":"MESH:C000657245"},{"subj":"1906","pred":"source","obj":"LitCovid-PubTator"},{"subj":"1907","pred":"source","obj":"LitCovid-PubTator"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}]},{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T114","span":{"begin":308,"end":323},"obj":"Body_part"},{"id":"T115","span":{"begin":327,"end":333},"obj":"Body_part"}],"attributes":[{"id":"A114","pred":"fma_id","subj":"T114","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A115","pred":"fma_id","subj":"T115","obj":"http://purl.org/sig/ont/fma/fma62970"},{"subj":"T114","pred":"source","obj":"LitCovid-PD-FMA-UBERON"},{"subj":"T115","pred":"source","obj":"LitCovid-PD-FMA-UBERON"}]},{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T375","span":{"begin":540,"end":548},"obj":"Disease"}],"attributes":[{"id":"A375","pred":"mondo_id","subj":"T375","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"subj":"T375","pred":"source","obj":"LitCovid-PD-MONDO"}]},{"project":"LitCovid-PD-CLO","denotations":[{"id":"T364","span":{"begin":327,"end":333},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"}],"attributes":[{"subj":"T364","pred":"source","obj":"LitCovid-PD-CLO"}]},{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T89792","span":{"begin":151,"end":168},"obj":"Chemical"},{"id":"T91905","span":{"begin":158,"end":168},"obj":"Chemical"}],"attributes":[{"id":"A80616","pred":"chebi_id","subj":"T89792","obj":"http://purl.obolibrary.org/obo/CHEBI_23924"},{"id":"A25044","pred":"chebi_id","subj":"T91905","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"subj":"T89792","pred":"source","obj":"LitCovid-PD-CHEBI"},{"subj":"T91905","pred":"source","obj":"LitCovid-PD-CHEBI"}]},{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T31","span":{"begin":262,"end":277},"obj":"http://purl.obolibrary.org/obo/GO_0006955"}],"attributes":[{"subj":"T31","pred":"source","obj":"LitCovid-PD-GO-BP"}]},{"project":"LitCovid-sentences","denotations":[{"id":"T464","span":{"begin":0,"end":219},"obj":"Sentence"},{"id":"T465","span":{"begin":220,"end":558},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"T464","pred":"source","obj":"LitCovid-sentences"},{"subj":"T465","pred":"source","obj":"LitCovid-sentences"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"LitCovid-PubTator","color":"#ec93bf","default":true},{"id":"LitCovid-PD-FMA-UBERON","color":"#93d9ec"},{"id":"LitCovid-PD-MONDO","color":"#ece593"},{"id":"LitCovid-PD-CLO","color":"#cb93ec"},{"id":"LitCovid-PD-CHEBI","color":"#93ecb1"},{"id":"LitCovid-PD-GO-BP","color":"#ec9793"},{"id":"LitCovid-sentences","color":"#93a9ec"}]}]}}